Phase II Open-Label, Single-Center Study Evaluating Safety and Efficacy of Pembrolizumab Following Induction with the Hypomethylating Agent Azacitidine in Patients with Advanced Pancreatic Cancer After Failure of First-Line Therapy.

Protocol: 
AAAR3554
Phase: 
II

Phase II Open-Label, Single-Center Study Evaluating Safety and Efficacy of Pembrolizumab Following Induction with the Hypomethylating Agent Azacitidine in Patients with Advanced Pancreatic Cancer After Failure of First-Line Therapy.

Are you Eligible? (Inclusion Criteria)

1)Age ≥18 years of age on day of signing informed consent.

? 2)Have a performance status of 0 or 1 using the ECOG Performance Scale within 3 days of first dose of study drug.

3)? Have a predicted life expectancy of greater than 3 months.

4) Confirmed diagnosis of pancreatic ductal adenocarcinoma through cell tissue diagnoses.

Specialty Area(s)

Immunotherapy

Trial Location

Herbert Irving Comprehensive Cancer Center
161 Fort Washington Ave.
Herbert Irving Pavilion
New York, NY 10032
United States